During this segment, David Crawford, MD, discusses immunotherapy’s role in castration-resistant prostate cancer (CRPC), and explains how the US Food and Drug Administration’s approval of sipuleucel-T has led to a paradigm shift in the way that CRPC is treated.
Dr Crawford explains the unique capabilities of immunotherapy for advanced disease when compared to conventional treatment options such as cytotoxic chemotherapy.
Additionally, David Quinn, MD, discusses hormonal therapy agents, the key clinical trials that have tested these treatment options, and explains how the trials have demonstrated improved outcomes in CRPC.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
CMS' 340B Repayment Proposal May Harm Vulnerable Hospitals, Reward Those With Higher Revenues
April 26th 2024The 340B hospitals not receiving an offsetting lump-sum payment from CMS following 2018-2022 cuts later ruled unlawful are disproportionately rural, publicly owned, and nonacademic, according to a new study.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen